ArticleMolecular and clinical oncology2024

Comparison of the efficacy of first‑/second‑generation EGFR‑tyrosine kinase inhibitors and osimertinib for EGFR‑mutant lung cancer with negative or low PD‑L1 expression.

Minehiko Inomata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.